



## King's Research Portal

DOI:

[10.1016/j.eururo.2016.07.023](https://doi.org/10.1016/j.eururo.2016.07.023)

*Document Version*

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Stattin, P., Sandin, F., Thomsen, F. B., Garmo, H., Robinson, D., Lissbrant, I. F., Jonsson, H., & Bratt, O. (2016). Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. *European Urology*.  
<https://doi.org/10.1016/j.eururo.2016.07.023>

### Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal


### Take down policy

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

available at [www.sciencedirect.com](http://www.sciencedirect.com)  
journal homepage: [www.europeanurology.com](http://www.europeanurology.com)



European Association of Urology



## Prostate Cancer

# Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study

Pär Stattin<sup>a,b,\*</sup>, Fredrik Sandin<sup>c</sup>, Frederik Birkebæk Thomsen<sup>d</sup>, Hans Garmo<sup>c,e</sup>, David Robinson<sup>b,f</sup>, Ingela Franck Lissbrant<sup>g</sup>, Håkan Jonsson<sup>h</sup>, Ola Bratt<sup>i,j</sup>

<sup>a</sup> Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; <sup>b</sup> Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University Hospital, Umeå, Sweden; <sup>c</sup> Regional Cancer Centre Uppsala Örebro, Uppsala University Hospital, Uppsala, Sweden; <sup>d</sup> Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; <sup>e</sup> King's College London, School of Medicine, Division of Cancer Studies, Cancer Epidemiology Group, London, UK; <sup>f</sup> Department of Urology, Ryhov Hospital, Jönköping, Sweden; <sup>g</sup> Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; <sup>h</sup> Department of Radiation Sciences, Umeå University, Umeå, Sweden; <sup>i</sup> Department of Translational Medicine, Division of Urological Cancer, Lund University, Lund, Sweden; <sup>j</sup> CamPARI Clinic, Department of Urology, Cambridge University Hospitals, Cambridge, UK

## Article info

### Article history:

Accepted July 15, 2016

### Associate Editor:

James Catto

### Keywords:

Prostate cancer  
Very high-risk  
Radical  
Treatment  
Semiecologic  
Nationwide  
Population-based  
PCBaSe

## Abstract

**Background:** Current guidelines recommend androgen deprivation therapy only for men with very high-risk prostate cancer (PCa), but there is little evidence to support this stance. **Objective:** To investigate the association between radical local treatment and mortality in men with very high-risk PCa.

**Design, setting, and participants:** Semiecologic study of men aged <80 yr within the Prostate Cancer data Base Sweden, diagnosed in 1998–2012 with very high-risk PCa (local clinical stage T4 and/or prostate-specific antigen [PSA] level 50–200 ng/ml, any N, and M0). Men with locally advanced PCa (local clinical stage T3 and PSA level <50 ng/ml, any N, and M0) were used as positive controls.

**Intervention:** Proportion of men who received prostatectomy or full-dose radiotherapy in 640 experimental units defined by county, diagnostic period, and age at diagnosis.

**Outcome measurements and statistical analysis:** PCa and all-cause mortality rate ratios (MRRs).

**Results and limitations:** Both PCa and all-cause mortality were half as high in units in the highest tertile of exposure to radical local treatment compared with units in the lowest tertile (PCa MRR: 0.51; 95% confidence interval [CI], 0.28–0.95; and all-cause MRR: 0.56; 95% CI, 0.33–0.92). The results observed for locally advanced PCa for highest versus lowest tertile of exposure were in agreement with results from randomized trials (PCa MRR: 0.75; 95% CI, 0.60–0.94; and all-cause MRR: 0.85; 95% CI, 0.72–1.00). Although the semiecologic design minimized selection bias on an individual level, the effect of high therapeutic activity could not be separated from that of high diagnostic activity.

**Conclusions:** The substantially lower mortality in units with the highest exposure to radical local treatment suggests that radical treatment decreases mortality even in men with very high-risk PCa for whom such treatment has been considered ineffective.

**Patient summary:** Men with very high-risk prostate cancer diagnosed and treated in units with the highest exposure to surgery or radiotherapy had a substantially lower mortality.

© 2016 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\* Corresponding author. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.  
Tel. +46 73 620 52 51; Fax: +46 090 12 53 96.  
E-mail address: [par.stattin@umu.se](mailto:par.stattin@umu.se) (P. Stattin).

<http://dx.doi.org/10.1016/j.eururo.2016.07.023>

0302-2838/© 2016 European Association of Urology. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article in press as: Stattin P, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol (2016), <http://dx.doi.org/10.1016/j.eururo.2016.07.023>

## 1. Introduction

There is no randomized controlled trial (RCT), to our knowledge, on the effect of radical local treatment in men with prostate cancer (PCa) in the “gray zone” between locally advanced and metastatic PCa. This risk category is often referred to as very high-risk PCa and is defined by local invasion into adjacent organs or very high levels of serum prostate-specific antigen (PSA) together with negative imaging findings for metastasis [1–4]. The prognosis is poor, and radical local treatment has generally not been considered beneficial, as the local tumor often is too advanced to eradicate and there is a high likelihood of undetected micrometastases. Consequently, clinical guidelines recommend androgen deprivation therapy (ADT) only for men with very high-risk PCa [1,2]. The only studies on radical local treatment for men with very high-risk PCa are small and retrospective [4–10]. These studies reported longer survival in men who underwent radical prostatectomy or full-dose radiotherapy than in men who received ADT only. The comparisons of treatment effects in observational studies are hampered by selection bias because most patients selected for radical local treatment have less adverse cancer characteristics than patients not receiving that treatment. Even if prognostic factors such as stage, grade, and PSA level are included in the analysis, there will be residual confounding in observational studies based on an analysis of treatment exposure on an individual level [11].

The use of radical local treatment for very high-risk PCa has varied during the past 15 years between Swedish counties, which are geographically well-defined administrative units providing health care to the entire population in their catchment area. This provided a natural experiment, allowing us to investigate the association of radical local treatment with mortality from very high-risk PCa in a semiecologic study in which the effects of selection bias for exposure to treatment on an individual level were minimized and comprehensive individual-level data on cancer characteristics, treatment, and outcome could still be used.

There is consistent evidence from RCTs that radiotherapy combined with ADT improves survival of men with locally advanced PCa [12–17]. To assess the validity of our results for very high-risk PCa, we also investigated the association between radical local treatment for locally advanced PCa and mortality with the same method as a positive control. The plausibility of our observations for the treatment effect on very high-risk PCa would be strengthened if we observed an association between radical local treatment of locally advanced PCa and mortality similar to the effect reported from the RCTs.

The aim of this study was to assess the association between radical local treatment and mortality in men with very high-risk PCa by relating exposure to radical local treatment on a population level in experimental units, defined by county, period, and age at diagnosis, to mortality from PCa and all causes using comprehensive individual-level data on cancer characteristics, treatment, and outcome.

## 2. Methods

Prostate Cancer data Base Sweden (PCBaSe) 3.0 contains information obtained from the National Prostate Cancer Register (NPCR) of Sweden on cancer characteristics at diagnosis and on primary treatment [18–20]. PCBaSe also includes information on comorbidity, assessed by the Charlson Comorbidity Index (CCI) based on discharge diagnosis from the Patient Registry; education level, income, and marital status from the LISA database; and cause and date of death obtained from the Cause of Death Registry [21–25]. The study population within PCBaSe for this study included men aged <80 yr of age diagnosed in 1998–2012 with very high-risk PCa (T4 and/or PSA level 50–200 ng/ml, any N, and M0). To assess the validity of our method, we separately studied the association of local treatment and mortality in men with locally advanced PCa (local clinical stage T3 and PSA level <50 ng/ml, any N, and M0). Registration in NPCR does not distinguish clinical local stage T3a from T3b.

The following variables in PCBaSe were used: age, year of PCa diagnosis, mode of detection, clinical local tumor stage, N stage, PSA level, Gleason score, CCI, educational level, marital status, primary registered treatment in NPCR, and county of residence. Gleason grade was grouped according to the five-tier Gleason grading groups [26,27]. NPCR includes comprehensive information on radiotherapy since 2008; for men diagnosed before 2008, data were retrieved directly from oncological radiotherapy information systems and local databases in oncology departments on type of radiotherapy, treatment time, total dose, and fractions in RetroRad (Retrospective Registration of Radiotherapy, a nation wide audit) [28]. There are currently 20 counties in Sweden, and a large majority of health care including diagnostic and therapeutic activity for PCa is provided in the county of residence of the patient within a tax-financed equal access system. The study was approved by the Research Ethics Board at Umeå University.

### 2.1. Statistical methods

Exposure was measured as the proportion of men who received primary radical local treatment, that is, radical prostatectomy or full-dose radiotherapy with or without ADT within 1 yr of diagnosis, for very high-risk and locally advanced PCa in 640 experimental units based on diagnostic county, 2-yr diagnostic periods (plus 2012), and age at diagnosis (<65, 65–69, 70–74, and 75–79 yr). For each experimental unit, the person-years at risk from date of diagnosis until death, emigration, or end of study period (December 31, 2013), whichever event came first, were calculated. In a Poisson model, the logarithm of person-years at risk was used as offset; the numbers of PCa-related deaths and deaths from any cause were used as outcome. Results are presented as mortality rate ratio (MRR) with 95% confidence intervals (CIs) for exposure in tertiles and continuous as a restricted cubic spline. The models included county as a categorical variable, year of diagnosis as a continuous variable, median Gleason grade groups as a

restricted cubic spline, mean PSA level, and CCI dichotomized into 0 vs  $\geq 1$ . Separate models were fitted for each age group, and a model for all ages combined was also fitted by including age group as a covariate. Multiple imputation was used to handle missing Gleason grade groups with the multivariate imputation by chained equations (MICE) algorithm [29]. The Gleason grade groups were imputed 20 times using all variables in Table 1 as predictors in the MICE algorithm. A separate model was fitted to the data set in each iteration and the results were then pooled using Rubin's rules [30]. The *p* value for trend was calculated by including exposure in the model as a continuous variable. Mortality rates per 1000 person-years were calculated by specifying different levels of exposure in the Poisson model and by using the underlying distribution for the other covariates values. All tests were two-sided, and the significance level was set to  $p < 0.05$ . Statistical analysis was performed with R v.3.1.2 software (R Foundation for Statistical Computing, Vienna, Austria).

### 3. Results

There were 106 204 men aged  $<80$  yr diagnosed with PCa in Sweden during the study period. Of these, 7500 men (7%) had very high-risk PCa and 10316 men (10%) had locally advanced PCa; for these men, there was a gradual increase in exposure to radical local treatment in most counties during the study period (Fig. 1) and an increase in the proportion receiving radical treatment in all age groups (Fig. 2). For instance, the proportion of men aged  $<65$  yr with very high-risk PCa who received radical treatment increased from 21% in 1998–1999 to 41% in 2012, whereas the corresponding increase for locally advanced PCa was from 46% to 79%. There was a more than nine-fold difference between the counties with the highest and lowest proportions of radical treatment for very high-risk PCa (28% vs 3%, respectively) and more than two-fold difference of radical treatment for locally advanced PCa (53% vs 20%, respectively) during the full study period in all age groups combined. The use of radical treatment for very high-risk PCa and locally advanced PCa in each county according to calendar year is depicted in Supplementary Figs. 1 and 2.

Clinical characteristics and cancer treatment for men with very high-risk and locally advanced PCa are presented in Table 1. Men in the units in the highest tertile of exposure to radical local treatment compared with men in units with the lowest exposure were younger and had lower PSA levels, fewer comorbidities, and fewer missing data for complete Gleason classification (3% vs 26%, respectively). In an analysis ignoring the restriction to M0 in the very high-risk group, 92% vs 65% of men had undergone bone imaging in the units with highest and lowest exposure, respectively (Supplementary Table 1).

Full-dose radiotherapy combined with ADT was the most common radical treatment; 8% of men with very high-risk PCa and 19% of men with locally advanced PCa received this treatment in the full study population. Details on the delivered radiotherapy are presented in Supplementary Table 2. Age was a strong determinant of receipt of radical

local treatment (Supplementary Fig. 3). Among men with very high-risk PCa, radical treatment was used in 32% of men aged  $<65$  yr but only 2% of men aged 75–79 yr, and the corresponding proportions for men with locally advanced PCa were 66% and 6%, respectively.

#### 3.1. Mortality according to exposure to local treatment

Men with very high-risk PCa in the units in the highest tertile of exposure to radical local treatment had half the mortality of men in the lowest tertile (PCa MRR: 0.51; 95% CI, 0.28–0.95; and all-cause MRR: 0.56; 95% CI, 0.33–0.92) (Table 2 and Fig. 3). The association between radical treatment and PCa mortality for highest versus lowest tertile of exposure was observed in all age groups up to 75 yr (age  $<65$  yr, MRR: 0.64; 95% CI, 0.30–1.38; age 65–69 yr, MRR: 0.32; 95% CI, 0.10–1.02; and age 70–74 yr, MRR: 0.88; 95% CI, 0.12–6.41). The absolute PCa-specific mortality for men with very high-risk PCa was 30 per 1000 person-years in the highest tertile of treatment and 58 per 1000 person-years in the lowest tertile; the absolute all-cause mortality for men with very high-risk PCa was 44 per 1000 person-years in the highest tertile and 79 per 1000 person-years in the lowest tertile.

Mortality in men with locally advanced PCa was also related to exposure to radical local treatment for the highest versus lowest tertile of exposure (PCa MRR: 0.75; 95% CI, 0.60–0.94; and all-cause MRR: 0.85; 95% CI, 0.72–1.00). The association between radical treatment and PCa mortality was observed in all age groups up to 75 yr (age  $<65$  yr, MRR: 0.75; 95% CI, 0.55–1.03; age 65–69 yr, MRR: 0.73; 95% CI, 0.51–1.04; and age 70–74 yr, MRR: 0.36; 95% CI, 0.11–1.13). All comparisons between tertiles of exposure to radical treatment showed a statistically significant association with PCa and all-cause MRR ( $p < 0.05$ ). Too few men aged  $>75$  yr received radical treatment to allow a separate analysis in this age group (Supplementary Fig. 3).

### 4. Discussion

In men with very high-risk PCa, mortality from PCa and that from all causes were half as high in units with the highest exposure to radical local treatment as in the units with the lowest exposure in this semiecologic, nationwide, population-based study. This strong association suggests that radical local treatment decreases mortality even in men with very high-risk PCa for whom radical treatment has previously been considered ineffective.

The semiecologic study design has several strengths [31,32]. Exposure to treatment could be assessed on a population level, which minimized selection bias on an individual level, while at the same time comprehensive, high-quality individual-level data for cancer characteristics, comorbidity, cancer treatment, and cause of death could be used [18–20,28].

Residual confounding cannot be ruled out. Some counties consistently had a higher use of radical local

**Table 1 – Distribution (percentage and interquartile range) of baseline characteristics for men with very high-risk and locally advanced prostate cancer according to experimental units in Prostate Cancer data Base Sweden 3.0**

|   | Very high-risk PCa                        |             |             | Total       |
|---|---|-------------|-------------|-------------|
|   | Radical treatment in experimental unit, % |             |             |             |
|   | 0–33                                      | 34–66       | 67–100      |             |
| Age at diagnosis, yr                            |   |             |             |             |
| <65   | 13 (0–0)                                  | 63 (0–100)  | 44 (0–100)  | 19 (0–0)    |
| 65–69   | 17 (0–0)                                  | 30 (0–100)  | 45 (0–100)  | 19 (0–0)    |
| 70–74   | 30 (0–100)                                | 7 (0–0)     | 8 (0–0)     | 27 (0–100)  |
| 75–79   | 40 (0–100)                                | 0 (0–0)     | 3 (0–0)     | 36 (0–75)   |
| Mode of detection <sup>a</sup>                  |   |             |             |             |
| Symptoms  | 36 (0–62)                                 | 41 (20–67)  | 48 (24–67)  | 37 (0–62)   |
| Screening                                       | 17 (0–26)                                 | 27 (11–33)  | 27 (0–50)   | 18 (0–29)   |
| Other reason                                    | 43 (20–75)                                | 29 (0–44)   | 21 (0–25)   | 41 (15–67)  |
| Missing   | 4 (0–0)                                   | 3 (0–0)     | 3 (0–0)     | 4 (0–0)     |
| T stage   |   |             |             |             |
| T1a/T1b   | 2 (0–0)                                   | 1 (0–0)     | 1 (0–0)     | 2 (0–0)     |
| T1c   | 12 (0–20)                                 | 20 (0–29)   | 18 (0–33)   | 13 (0–20)   |
| T2  | 27 (15–36)                                | 25 (10–38)  | 26 (0–40)   | 27 (14–36)  |
| T3  | 44 (33–56)                                | 41 (25–50)  | 47 (25–61)  | 43 (33–56)  |
| T4  | 14 (0–20)                                 | 11 (0–20)   | 7 (0–3)     | 13 (0–20)   |
| TX/missing                                      | 1 (0–0)                                   | 1 (0–0)     | 2 (0–0)     | 1 (0–0)     |
| N stage   |   |             |             |             |
| N0  | 8 (0–17)                                  | 24 (0–40)   | 26 (0–53)   | 10 (0–20)   |
| N1  | 4 (0–5)                                   | 8 (0–17)    | 4 (0–0)     | 4 (0–7)     |
| NX/missing                                      | 89 (75–100)                               | 68 (50–86)  | 69 (44–100) | 86 (69–100) |
| PSA level, ng/ml                                |   |             |             |             |
| <20   | 4 (0–5)                                   | 3 (0–0)     | 2 (0–0)     | 4 (0–4)     |
| 20–<50  | 4 (0–6)                                   | 2 (0–0)     | 2 (0–0)     | 4 (0–5)     |
| 50–<75  | 41 (30–50)                                | 49 (33–60)  | 58 (48–81)  | 42 (33–54)  |
| 75–<100   | 23 (14–33)                                | 20 (0–33)   | 23 (0–35)   | 22 (12–33)  |
| 100–<200  | 28 (18–38)                                | 26 (12–33)  | 15 (0–25)   | 28 (17–36)  |
| Gleason grade group <sup>b</sup>                |   |             |             |             |
| 1   | 14 (0–21)                                 | 13 (0–20)   | 13 (0–21)   | 14 (0–20)   |
| 2   | 13 (0–21)                                 | 19 (0–33)   | 14 (0–25)   | 13 (0–24)   |
| 3   | 13 (0–26)                                 | 19 (0–25)   | 29 (0–45)   | 14 (0–27)   |
| 4   | 17 (7–29)                                 | 22 (7–33)   | 24 (0–33)   | 18 (6–29)   |
| 5   | 16 (0–25)                                 | 19 (0–26)   | 18 (0–35)   | 17 (0–26)   |
| Missing   | 26 (0–33)                                 | 8 (0–0)     | 3 (0–0)     | 24 (0–25)   |
| Charlson Comorbidity Index                      |   |             |             |             |
| 0   | 69 (60–83)                                | 83 (78–100) | 91 (81–100) | 71 (62–88)  |
| 1   | 16 (0–24)                                 | 9 (0–18)    | 4 (0–0)     | 15 (0–22)   |
| ≥2  | 15 (0–20)                                 | 8 (0–9)     | 5 (0–0)     | 14 (0–19)   |
| Education level                                 |   |             |             |             |
| Low, <10 yr                                     | 50 (37–64)                                | 32 (20–50)  | 32 (0–45)   | 48 (33–61)  |
| Intermediate, 10–12 yr                          | 34 (22–45)                                | 42 (27–56)  | 44 (28–76)  | 35 (23–50)  |
| High, >12 yr                                    | 15 (0–22)                                 | 25 (10–33)  | 21 (0–26)   | 16 (0–25)   |
| Missing   | 1 (0–0)                                   | 1 (0–0)     | 2 (0–0)     | 1 (0–0)     |
| Marital status                                  |   |             |             |             |
| Unmarried                                       | 10 (0–17)                                 | 18 (0–27)   | 13 (0–21)   | 11 (0–20)   |
| Married   | 66 (56–75)                                | 62 (50–75)  | 66 (50–81)  | 66 (52–75)  |
| Divorced  | 15 (0–22)                                 | 18 (0–25)   | 16 (0–21)   | 15 (0–23)   |
| Widower   | 9 (0–14)                                  | 3 (0–0)     | 5 (0–0)     | 9 (0–12)    |
| Missing   | 0 (0–0)                                   | 0 (0–0)     | 0 (0–0)     | 0 (0–0)     |
| Primary treatment                               |   |             |             |             |
| Radical prostatectomy                           | 1 (0–0)                                   | 12 (0–18)   | 13 (0–25)   | 3 (0–0)     |
| Radiotherapy with ADT                           | 4 (0–6)                                   | 31 (22–50)  | 68 (50–100) | 8 (0–20)    |
| Radiotherapy only/other radical local treatment | 2 (0–0)                                   | 6 (0–10)    | 2 (0–0)     | 2 (0–0)     |
| All ADTs  | 79 (70–90)                                | 44 (33–53)  | 16 (0–25)   | 75 (60–87)  |
| GnRH with or without AA flare protection        | 54 (40–67)                                | 27 (16–38)  | 13 (0–25)   | 51 (30–64)  |
| GnRH with AA continuous                         | 2 (0–0)                                   | 3 (0–0)     | 0 (0–0)     | 3 (0–0)     |
| AA monotherapy                                  | 14 (0–25)                                 | 12 (0–20)   | 3 (0–0)     | 14 (0–22)   |
| Surgical castration                             | 9 (0–12)                                  | 2 (0–0)     | 0 (0–0)     | 8 (0–10)    |
| Conservative/other noncurative/missing          | 14 (0–20)                                 | 7 (0–11)    | 1 (0–0)     | 13 (0–17)   |
| Locally advanced PCa                            |   |             |             | Total       |
| Radical treatment in experimental unit, %       |   |             |             |             |
|   | 0–33                                      | 34–66       | 67–100      |             |
| Age at diagnosis, yr                            |   |             |             |             |
| <65   | 3 (0–0)                                   | 29 (0–100)  | 61 (0–100)  | 22 (0–0)    |



Table 1 (Continued)

|   | Locally advanced PCa                      |               |               | Total         |
|---|---|---------------|---------------|---------------|
|   | Radical treatment in experimental unit, % |               |               |               |
|   | 0–33                                      | 34–66         | 67–100        |               |
| 65–69   | 8 (0–0)                                   | 40 (0–100)    | 31 (0–100)    | 23 (0–0)      |
| 70–74   | 32 (0–100)                                | 29 (0–100)    | 6 (0–0)       | 26 (0–0)      |
| 75–79   | 58 (0–100)                                | 1 (0–0)       | 1 (0–0)       | 29 (0–100)    |
| Mode of detection <sup>a</sup>                  |   |               |               |               |
| Symptoms  | 34 (0–60)                                 | 31 (10–54)    | 36 (20–57)    | 34 (3–57)     |
| Screening                                       | 18 (7–25)                                 | 31 (14–39)    | 37 (20–50)    | 26 (11–37)    |
| Other reason                                    | 44 (14–76)                                | 31 (12–47)    | 24 (0–33)     | 36 (12–50)    |
| Missing   | 3 (0–3)                                   | 7 (0–3)       | 4 (0–0)       | 5 (0–2)       |
| T stage   |   |               |               |               |
| T3  | 100 (100–100)                             | 100 (100–100) | 100 (100–100) | 100 (100–100) |
| N stage   |   |               |               |               |
| N0  | 10 (0–17)                                 | 31 (17–43)    | 33 (10–53)    | 21 (0–38)     |
| N1  | 3 (0–5)                                   | 9 (0–17)      | 8 (0–12)      | 6 (0–10)      |
| NX/missing                                      | 87 (78–100)                               | 60 (46–76)    | 59 (40–87)    | 73 (50–97)    |
| PSA level, ng/ml                                |   |               |               |               |
| <20   | 55 (44–67)                                | 63 (50–71)    | 67 (57–79)    | 60 (50–71)    |
| 20–<50  | 45 (33–56)                                | 37 (29–50)    | 33 (21–43)    | 40 (29–50)    |
| Gleason grade group <sup>b</sup>                |   |               |               |               |
| 1   | 20 (6–29)                                 | 21 (0–28)     | 19 (0–30)     | 20 (0–29)     |
| 2   | 16 (0–25)                                 | 21 (4–30)     | 24 (12–33)    | 19 (0–29)     |
| 3   | 12 (0–22)                                 | 18 (0–29)     | 22 (10–33)    | 16 (0–27)     |
| 4   | 14 (2–20)                                 | 16 (6–26)     | 15 (0–22)     | 15 (0–23)     |
| 5   | 12 (0–20)                                 | 13 (0–25)     | 15 (0–25)     | 13 (0–23)     |
| Missing   | 27 (0–37)                                 | 12 (0–9)      | 5 (0–0)       | 18 (0–17)     |
| Charlson Comorbidity Index                      |   |               |               |               |
| 0   | 69 (61–81)                                | 79 (70–88)    | 83 (75–100)   | 75 (67–88)    |
| 1   | 17 (8–23)                                 | 12 (0–19)     | 10 (0–17)     | 14 (0–21)     |
| ≥2  | 14 (6–18)                                 | 9 (0–13)      | 7 (0–11)      | 11 (0–15)     |
| Education level                                 |   |               |               |               |
| Low, <10 yr                                     | 52 (43–66)                                | 41 (33–57)    | 34 (23–45)    | 45 (33–60)    |
| Intermediate, 10–12 yr                          | 32 (21–41)                                | 38 (27–48)    | 42 (31–55)    | 36 (25–45)    |
| High, >12 yr                                    | 15 (6–20)                                 | 20 (5–27)     | 24 (9–31)     | 18 (6–25)     |
| Missing   | 1 (0–0)                                   | 1 (0–0)       | 1 (0–0)       | 1 (0–0)       |
| Marital status                                  |   |               |               |               |
| Unmarried                                       | 8 (0–12)                                  | 11 (0–18)     | 14 (0–24)     | 10 (0–17)     |
| Married   | 71 (62–80)                                | 68 (58–78)    | 66 (56–80)    | 69 (58–79)    |
| Divorced  | 11 (0–17)                                 | 17 (6–25)     | 17 (0–24)     | 14 (0–21)     |
| Widower   | 10 (0–14)                                 | 5 (0–8)       | 3 (0–0)       | 7 (0–10)      |
| Missing   | 0 (0–0)                                   | 0 (0–0)       | 0 (0–0)       | 0 (0–0)       |
| Primary treatment                               |   |               |               |               |
| Radical prostatectomy                           | 2 (0–0)                                   | 12 (0–20)     | 19 (0–25)     | 8 (0–12)      |
| Radiotherapy with ADT                           | 5 (0–8)                                   | 27 (16–38)    | 45 (30–71)    | 19 (0–37)     |
| Radiotherapy only/other radical local treatment | 4 (0–5)                                   | 14 (0–20)     | 16 (0–25)     | 9 (0–14)      |
| All ADTs  | 62 (50–76)                                | 33 (27–44)    | 15 (0–20)     | 44 (22–62)    |
| GnRH with or without AA flare protection        | 42 (27–53)                                | 20 (11–30)    | 10 (0–12)     | 29 (9–40)     |
| GnRH with AA continuous                         | 1 (0–0)                                   | 2 (0–0)       | 2 (0–0)       | 2 (0–0)       |
| AA monotherapy                                  | 12 (0–21)                                 | 9 (0–17)      | 4 (0–5)       | 10 (0–15)     |
| Surgical castration                             | 6 (0–11)                                  | 1 (0–0)       | 0 (0–0)       | 4 (0–4)       |
| Conservative/other noncurative/missing          | 27 (14–36)                                | 15 (0–18)     | 5 (0–7)       | 19 (0–25)     |

Experimental units according to age at diagnosis, diagnostic year, and county of residency. AA = per oral antiandrogen; ADT = androgen deprivation therapy; GnRH = gonadotropin-releasing hormone agonist; IQR = interquartile range; PSA = prostate-specific antigen.

<sup>a</sup> Data available for cases diagnosed after January 1, 2000.

<sup>b</sup> According to the five-tier Gleason grade groups according to the International Society of Urological Pathology [26,27], Gleason grade group 1 = Gleason score 2–6; Gleason grade group 2 = Gleason score 7 (3 + 4); Gleason grade group 3 = Gleason score 7 (4 + 3); Gleason grade group 4 = Gleason score 8; and Gleason grade group 5 = Gleason score 9–10.

treatment, and there may have been factors unrelated to treatment causing the lower mortality in these counties. Although the analysis was adjusted for county and year of diagnosis, there may have been interactions between these two factors that were left unaccounted for. High exposure to radical local treatment was linked to high exposure to staging investigations, including bone and lymph node imaging and complete Gleason classification. The design of

the study allowed for an investigation of the association of a high diagnostic activity and a high therapeutic activity, assessed on a population level, with oncological outcome, assessed on an individual level, but the effects of diagnostic and therapeutic activity could not be separated.

Most men aged <75 yr with very high-risk PCa die of their cancer [33,34]. Despite this, radical local treatment of the primary tumor in addition to ADT has only been




Fig. 1 – Distribution of exposure to radical local treatment in experimental units of county and 2-yr periods of diagnosis in men with locally advanced and very high-risk prostate cancer.


\* Counties with a university hospital.

evaluated in some reports from small, single-institution case series [4–10]. These studies reported longer survival for men with very high-risk PCa who received full-dose radiotherapy or prostatectomy in addition to ADT, but selection bias cannot be ruled out as the only cause of these findings. In contrast, multimodal treatment of very advanced breast cancer is a well-researched area. There is strong evidence from RCTs that combinations of local and systemic treatment prolong survival, and combined treatment has long been the standard of care for women with very advanced breast cancer [35].

RCTs of ADT and radical prostatectomy or radiotherapy in men with very high-risk PCa (with or without confirmed limited metastatic spread) are ongoing [36–40], but their results will not be available for many years. Results from large, well-designed studies based on registers with

high-quality data can fill the current lack of evidence. This study included virtually all PCa cases in an entire nation, with comprehensive data from high-quality health care registries and demographic databases on cancer characteristics, cancer treatment, comorbidity, socioeconomic factors, and health care providers [18–20]. We also investigated the association between radical local treatment and mortality from locally advanced PCa (local clinical stage T3). The magnitude of the association between high exposure to radical local treatment and the decrease in mortality in men with locally advanced PCa was in accordance with the effect of local treatment reported from RCTs [12–17], implying that the methods we used yielded accurate risk estimates.

In this study, lymph node metastasis detected at surgery (pN1) was not used as an inclusion criterion because men




**Fig. 2 – Percentage of men with very high-risk (local clinical stage T4 and/or prostate-specific antigen [PSA] level 50–200 ng/ml, any N, and all M0) or locally advanced (local clinical stage T3 and PSA level <50 ng/ml, any N, and all M0) prostate cancer who received primary radical local treatment in 2-yr periods stratified according to age groups.**  
PCa = prostate cancer.

**Table 2 – Mortality rate ratio with 95% confidence intervals by risk group, age group, and percentage with radical treatment**

| Age at diagnosis, yr                    |          |          |              |          |          |              |          |          |              |          |          |             |
|---|----------|----------|--------------|----------|----------|--------------|----------|----------|--------------|----------|----------|-------------|
| <65                                     |          |          | 65–69        |          |          | 70–74        |          |          | Total (<75)  |          |          |             |
| Person-years                            | MRR      | (95% CI) | Person-years | MRR      | (95% CI) | Person-years | MRR      | (95% CI) | Person-years | MRR      | (95% CI) |             |
| Very high-risk PCa                      |          |          |              |          |          |              |          |          |              |          |          |             |
| Death from PCa                          |          |          |              |          |          |              |          |          |              |          |          |             |
| Radical treatment, %                    |          |          |              |          |          |              |          |          |              |          |          |             |
| 0–33                                    | 6156.6   | 1.00     | (Reference)  | 7460.8   | 1.00     | (Reference)  | 11 900.6 | 1.00     | (Reference)  | 25 518   | 1.00     | (Reference) |
| 34–66                                   | 2944.7   | 0.80     | (0.65–0.99)  | 1100.2   | 0.81     | (0.58–1.12)  | 248.4    | 0.73     | (0.37–1.44)  | 4293.3   | 0.80     | (0.67–0.96) |
| 67–100                                  | 260.3    | 0.64     | (0.30–1.38)  | 219.8    | 0.32     | (0.10–1.02)  | 23.7     | 0.88     | (0.12–6.41)  | 503.8    | 0.51     | (0.28–0.95) |
| Death from all causes                   |          |          |              |          |          |              |          |          |              |          |          |             |
| Radical treatment, %                    |          |          |              |          |          |              |          |          |              |          |          |             |
| 0–33                                    | 6156.6   | 1.00     | (Reference)  | 7460.8   | 1.00     | (Reference)  | 11 900.6 | 1.00     | (Reference)  | 25 518   | 1.00     | (Reference) |
| 34–66                                   | 2944.7   | 0.84     | (0.70–1.01)  | 1100.2   | 0.92     | (0.71–1.20)  | 248.4    | 0.80     | (0.47–1.36)  | 4293.3   | 0.86     | (0.74–1.00) |
| 67–100                                  | 260.3    | 0.59     | (0.29–1.20)  | 219.8    | 0.53     | (0.25–1.13)  | 23.7     | 0.54     | (0.07–3.91)  | 503.8    | 0.56     | (0.33–0.92) |
| Locally advanced PCa                    |          |          |              |          |          |              |          |          |              |          |          |             |
| Death from PCa                          |          |          |              |          |          |              |          |          |              |          |          |             |
| Radical treatment, %                    |          |          |              |          |          |              |          |          |              |          |          |             |
| 0–33                                    | 1652.0   | 1.00     | (Reference)  | 3400.6   | 1.00     | (Reference)  | 12 326.2 | 1.00     | (Reference)  | 17 378.8 | 1.00     | (Reference) |
| 34–66                                   | 8644.3   | 0.77     | (0.57–1.04)  | 10 292.6 | 0.93     | (0.74–1.18)  | 5548.3   | 0.81     | (0.66–1.00)  | 24 485.3 | 0.84     | (0.72–0.98) |
| 67–100                                  | 7847.3   | 0.75     | (0.55–1.03)  | 3227.6   | 0.73     | (0.51–1.04)  | 433.2    | 0.36     | (0.11–1.13)  | 11 508.2 | 0.75     | (0.60–0.94) |
| Death from all causes                   |          |          |              |          |          |              |          |          |              |          |          |             |
| Radical treatment, %                    |          |          |              |          |          |              |          |          |              |          |          |             |
| 0–33                                    | 1652.0   | 1.00     | (Reference)  | 3400.6   | 1.00     | (Reference)  | 12 326.2 | 1.00     | (Reference)  | 17 378.8 | 1.00     | (Reference) |
| 34–66                                   | 8644.3   | 0.77     | (0.60–0.99)  | 10 292.6 | 0.97     | (0.82–1.15)  | 5548.3   | 0.91     | (0.79–1.05)  | 24 485.3 | 0.91     | (0.81–1.01) |
| 67–100                                  | 7847.3   | 0.79     | (0.61–1.02)  | 3227.6   | 0.86     | (0.67–1.11)  | 433.2    | 0.63     | (0.35–1.14)  | 11 508.2 | 0.85     | (0.72–1.00) |
| Locally advanced and very high-risk PCa |          |          |              |          |          |              |          |          |              |          |          |             |
| Death from PCa                          |          |          |              |          |          |              |          |          |              |          |          |             |
| Radical treatment, %                    |          |          |              |          |          |              |          |          |              |          |          |             |
| 0–33                                    | 4129.4   | 1.00     | (Reference)  | 11 145.6 | 1.00     | (Reference)  | 26 397   | 1.00     | (Reference)  | 41 672   | 1.00     | (Reference) |
| 34–66                                   | 18 861.5 | 0.97     | (0.81–1.15)  | 13 172.5 | 0.98     | (0.85–1.13)  | 3851.5   | 1.00     | (0.81–1.23)  | 35 885.5 | 0.98     | (0.88–1.09) |
| 67–100                                  | 4514.4   | 0.82     | (0.63–1.06)  | 1383.4   | 0.83     | (0.56–1.23)  | 232.1    | 0.44     | (0.14–1.38)  | 6129.9   | 0.80     | (0.65–1.00) |
| Death from all causes                   |          |          |              |          |          |              |          |          |              |          |          |             |
| Radical treatment, %                    |          |          |              |          |          |              |          |          |              |          |          |             |
| 0–33                                    | 4129.4   | 1.00     | (Reference)  | 11 145.6 | 1.00     | (Reference)  | 26 397   | 1.00     | (Reference)  | 41 672   | 1.00     | (Reference) |
| 34–66                                   | 18 861.5 | 0.95     | (0.82–1.10)  | 13 172.5 | 0.97     | (0.87–1.09)  | 3851.5   | 1.02     | (0.87–1.18)  | 35 885.5 | 0.98     | (0.90–1.06) |
| 67–100                                  | 4514.4   | 0.82     | (0.66–1.02)  | 1383.4   | 0.92     | (0.69–1.23)  | 232.1    | 0.55     | (0.26–1.16)  | 6129.9   | 0.84     | (0.71–1.00) |

CI = confidence interval; MRR = mortality rate ratio; PCa, prostate cancer.





**Fig. 3 – Mortality rate ratio for death from prostate cancer (PCa) (orange) and all causes (blue) with 95% confidence interval in men with very high-risk (local clinical stage T4 and/or prostate-specific antigen [PSA] level 50–200 ng/ml, any N, and all M0) or locally advanced (local clinical stage T3 and PSA level <50 ng/ml, any N, and all M0) PCa according to proportion of men undergoing primary radical local treatment in experimental units based on age, year of diagnosis, and county. MRR = mortality rate ratio.**

with pN1 detected at prostatectomy for clinically localized PCa have a better prognosis than men with stage T4 cancer or a PSA level of 50–200 ng/ml [8,33]. Had pN1 disease been included in the very high-risk PCa group, more men in this subgroup with favorable prognosis would have been included in units with high exposure to radical local treatment, and this would have introduced selection bias.

## 5. Conclusions

In this semiecologic, nationwide, population-based study, mortality among men with very high-risk PCa (defined as local stage T4, PSA level 50–200 ng/ml, and M0) in experimental units with the highest exposure to radical local treatment was half that from PCa and all causes in units with the lowest exposure. This suggests that radical local treatment decreases mortality in men with very high-risk PCa for whom radical treatment has previously been considered ineffective. RCTs are needed to conclusively evaluate the effect of radical local treatment in men with very high-risk PCa.

**Author contributions:** Pär Stattin had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Stattin, Sandin, Garmo, Jonsson, Bratt.

**Acquisition of data:** Stattin, Robinson, Lissbrant, Bratt.

**Analysis and interpretation of data:** Stattin, Sandin, Thomsen, Garmo, Robinson, Lissbrant, Jonsson, Bratt.

**Drafting of the manuscript:** Stattin, Thomsen.

**Critical revision of the manuscript for important intellectual content:** Stattin, Sandin, Thomsen, Garmo, Robinson, Lissbrant, Jonsson, Bratt.

**Statistical analysis:** Stattin, Sandin, Thomsen.

**Obtaining funding:** Stattin.

**Administrative, technical, or material support:** None.

**Supervision:** None.

**Other (specify):** None.

**Financial disclosures:** Pär Stattin certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

**Funding/Support and role of the sponsor:** This work was supported by grant 825-2012-5047 from the Swedish Research Council and grant 130428 from the Swedish Cancer Society. Thomsen is supported by research grant from IMK Almene Fond.

**Acknowledgments:** This project was made possible by the continuous work of the National Prostate Cancer Register of Sweden (NPCR) steering group: Pär Stattin (chairman), Anders Widmark, Camilla Thellenberg Karlsson, Ove Andrén, Ann-Sofi Fransson, Magnus Törnblom, Stefan Carlsson, Marie Hjälme-Eriksson, David Robinson, Mats Andén, Jonas Hugosson, Ingela Franck Lissbrant, Johan Stranne, Maria Nyberg, Göran Ahlgren, René Blom, Lars Egevad, Calle Waller, Olof Akre, Per Fransson, Eva Johansson, Fredrik Sandin, and Karin Hellström.

## Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.eururo.2016.07.023>.

## References

- [1] Heidenreich A, Bastian PJ, Bellmunt J, et al. European Association of Urology. EAU guidelines on prostate cancer, part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. *Eur Urol* 2014;65:467–79.
- [2] Mohler JL, Armstrong AJ, Bahnson RR, et al. Prostate cancer, version 1. 2016. *J Natl Compr Canc Netw* 2016;14:19–30.
- [3] Oderda M, Joniau S, Spahn M, Gontero P. Debulking surgery in the setting of very high-risk prostate cancer scenarios. *BJU Int* 2012;110:E192–8.
- [4] Moltzahn F, Karnes J, Gontero P, et al. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. *Prostate Cancer Prostatic Dis* 2015;18:31–7.
- [5] Lilleby W, Narrang A, Tafjord G, et al. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy. *Radiat Oncol* 2015;10:232.
- [6] Gontero P, Spahn M, Tombal B, et al. Is there a prostate-specific antigen upper limit for radical prostatectomy? *BJU Int* 2011;108:1093–100.
- [7] Tai P, Tonita J, Woitas C, Zhu T, Joseph K, Skarsgard D. Treatment outcomes in non-metastatic prostate cancer patients with ultra-high prostate-specific antigen. *Int J Radiat Oncol Biol Phys* 2012;83:e525–30.
- [8] Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. *J Urol* 1999;161:1223–7, discussion 1227–8.
- [9] Engel J, Bastian PJ, Baur H, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. *Eur Urol* 2010;57:754–61.
- [10] Gakis G, Boorjian SA, Briganti A, et al. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature. *Eur Urol* 2014;66:191–9.
- [11] Stattin P, Loeb S. To measure is to know. If you cannot measure it, you cannot improve it: statistical modeling cannot compensate for unmeasured bias. *Eur Urol* 2014;65:701–3.
- [12] Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. *J Clin Oncol* 2008;26:585–91.
- [13] Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. *Lancet Oncol* 2011;12:451–9.
- [14] Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. *Lancet* 2009;373:301–8.
- [15] Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. *Lancet Oncol* 2010;11:1066–73.
- [16] Mottet N, Peneau M, Mazon J-J, Molin V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. *Eur Urol* 2012;62:213–9.
- [17] Mason MD, Parulekar WR, Sydes MR, et al. Final report of the Intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. *J Clin Oncol* 2015;33:2143–50.
- [18] Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. *Int J Epidemiol* 2013;42:956–67.
- [19] Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of the National Prostate Cancer Register of Sweden. *Acta Oncol* 2015;54:158–63.
- [20] Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. *Eur J Cancer* 2015;51:101–11.
- [21] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–83.
- [22] Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. *J Urol* 2011;185:833–9.
- [23] Longitudinal integration database for health insurance and labour market studies (LISA by Swedish acronym). Statistics Sweden Web site. <http://www.scb.se/en/Services/Guidance-for-researchers-and-universities/SCB-Data/Longitudinal-integration-database-for-health-insurance-and-labour-market-studies-LISA-by-Swedish-acronym/>.
- [24] Fall K, Strömberg F, Rosell J, Andrén O, Varenhorst E, South-East Region Prostate Cancer Group. Reliability of death certificates in prostate cancer patients. *Scand J Urol Nephrol* 2008;42:352–7.
- [25] Godtman R, Holmberg E, Stranne J, Hugosson J. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. *Scand J Urol Nephrol* 2011;45:226–32.
- [26] Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. *Eur Urol* 2016;69:428–35.
- [27] Loeb S, Folkvaljon Y, Robinson D, Lissbrant IF, Egevad L, Stattin P. Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort. *Eur Urol* 2016;69:1135–41.
- [28] Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort profile update: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base: a refined prostate cancer trajectory. *Int J Epidemiol* 2016;45:73–82.
- [29] Buuren S. Flexible imputation of missing data. London, UK: Chapman & Hall/CRC; 2012.

- [30] Rubin D. Multiple imputation for nonresponse in surveys. New York, NY: John Wiley & Sons; 2004.
- [31] Greenland S, Morgenstern H. Ecological bias, confounding, and effect modification. *Int J Epidemiol* 1989;18:269–74.
- [32] Wakefield J. Ecologic studies revisited. *Annu Rev Public Health* 2008;29:75–90.
- [33] Akre O, Garmo H, Adolfsson J, Lambe M, Bratt O, Stattin P. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. *Eur Urol* 2011;60:554–63.
- [34] Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study. *Eur Urol* 2013;63:88–96.
- [35] Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, version 1.2016. *J Natl Compr Canc Netw* 2015;13:1475–85.
- [36] Parker CC, Sydes MR, Mason MD, et al. Prostate radiotherapy for men with metastatic disease: a new comparison in the STAMPEDE trial. *Clin Oncol (R Coll Radiol)* 2013;25:318–20.
- [37] Impact of radical prostatectomy as primary treatment in patients with prostate cancer with limited bone metastases (g-RAMPP). ClinicalTrials.gov Web site. <https://clinicaltrials.gov/show/NCT02454543>.
- [38] Local treatment with RP for newly-diagnosed mPCa (LoMP). ClinicalTrials.gov Web site. <https://clinicaltrials.gov/show/NCT02138721>.
- [39] Cytoreductive prostatectomy in treating patients with newly diagnosed, metastatic prostate cancer. ClinicalTrials.gov Web site. <https://clinicaltrials.gov/show/NCT02458716>.
- [40] Testing radical prostatectomy in men with oligometastatic prostate cancer that has spread to the bone. BioMed Central Web site. <http://www.isrctn.com/ISRCTN15704862>.